IE44685B1 - Methyl 3-(2-quinoxalinylmethylene)carbazate-n1,n4-dioxides - Google Patents
Methyl 3-(2-quinoxalinylmethylene)carbazate-n1,n4-dioxidesInfo
- Publication number
- IE44685B1 IE44685B1 IE1629/81A IE162981A IE44685B1 IE 44685 B1 IE44685 B1 IE 44685B1 IE 1629/81 A IE1629/81 A IE 1629/81A IE 162981 A IE162981 A IE 162981A IE 44685 B1 IE44685 B1 IE 44685B1
- Authority
- IE
- Ireland
- Prior art keywords
- compounds
- formula
- methyl
- dioxides
- compound
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
The invention relates to novel methyl 3-(2-quinoxalinylmethylene) 1 4 .
carbazate Ν ,N -dioxides with useful antibacterial properties and/or with growth promotant properties in animals.
According to our Patent Specification No. (44684 ) a P>'°cess Lor preparing a methyl 3-(2-quinoxalinylmethylene)carbazate Ν^,Ν4dioxide of the formula:
wherein R is hydrogen, alkyl, hydroxyalkyl, alkanoyl, benzoyl or 12 . 'l 2
-CONR R wherein R and R are each hydrogen, alkyl, hydroxyalkyl or 10 aminoalkyl, any such alkyl, hydroxyalkyl or aminoalkyl group containing 1 to 6 carbon atoms and any such alkanoyl group containing 2 to 7 carbon atoms, comprises reacting a compound of the formula:
wherein R is as defined above and X is chlorine or bromine, with 15 a compound of the formula:
R3-NE-NH-COOCH3 (III)
4685
- 3 wherein R3 is an aliphatic or aromatic sulphonyl group, in a reaction-inert solvent, in the presence of anhydrous potassium carbonate.
Compounds of formula (I), other than those in which R is 1 2 hydrogen, alkyl or -CONR R , are novel compounds. Thus the invention provides methyl 3-(3-substituted-2-quinoxalinylmethylene) carbazate
4
Ν' ,N -dioxides of the formula:
wherein R is hydroxyalkyl containing 1 to 6 carbon atoms, alkanoyl containing 2 to 7 carbon atoms, or benzoyl.
Compounds of formula (I) in which R is hydrogen or alkyl containing 1 to 6 carbon atoms are described and claimed in British 1 2
Patent Specification No. 1058047, while those in which R is -CONR R are described and claimed in British Patent Specification No.
1365441.
The compounds of formula (XI) used as starting materials in preparing the compounds of the invention may be prepared by chlorina1 4 tion or bromination of 2-methyl-quinoxaline N ,N -dioxides by the general methods described in J. Chem. Soc. 2052, (1956), Chemistry of Heterocyclic Compounds, 940 (1967) and in U.S. Patent No. 3753987. 1 4
The 2-methyl-quinoxaline N ,N -dioxides are themselves prepared by methods as described in J. Chem. Soc., 322 (1943), U.S. Patents Nos.
4 e 8 5
3474097, 3553208 and 3660498 and British Patent Specification No. 1215815.
Some of the compounds of formula (III) are novel compounds, the subject of our Patent Specification No. (1630/81) filed concurrently herewith. Others are the subject of British Patent no. 1505120.
The process for preparing compounds of formula (IV) according to the invention may be illustrated by the reaction of the compound of formula (II) with N-methoxycarbonyl-Ν'-trifyl-hydrazine in the presence of anhydrous potassium carbonate as follows:-
4468S
- 5 A suspension of the 2-halomethylquinoxaline, N^.N’-dicxide in a reaction-inert solvent such as acetonitrile is heated with stirring at a teaperature of from 75 to S5CC., preferably at reflux temperature. One to two molar equivalents, preferably a slight molar excess, of anhydrous powdered potassium carbonate and N-methoxycarbonyl -Ν' -trifylhydrazine are added to the suspension in one portion.
In those cases where a solid separates within a few minutes, heating is continued for 30-40 minutes, and then the solid is collected and dried. Where no solid separates, heating is continued until thin layer chromatography indicates the absence of the original 2-halomethylquinoxaline di-N-oxide. The reaction mixture is filtered and the filtrate is concentrated under vacuum at room temperature to give an amber oil which crystallizes from absolute ethanol.
The quinoxaline derivatives of this invention show strong antibacterial effects against Gram-positive and Gram-negative bacteria.
As a result of this activity, the compounds are useful as industrial antimicrobials, e.g., in water treatment, slime control, paint preservation and wood preservation as well as for topical application purposes as disinfectants.
Further, compounds of this invention are useful in veterinary medicine for the treatment of infections in animals. For oral administration dosages of from 1 mg/kg to 60 mg/kg of body weight may be employed. In the case of poultry and domestic animals, a compound is conveniently administered by mixing with feed or as a dilute solution or suspension, e.g. 0.1% solution for drinking purposes.
44685
- 6 The compounds of this invention are preferably administered by subcutaneous or intramuscular injection at a dosage of from 10 to 100 mg/kg of body weight. Vehicles suitable for parenteral injection may be either aqueous such as water, isotonic saline and isotonic dextrose, or non-aqueous such as fatty oils of vegetable origin, glycerol, propylene glycol and sorbitol.
The compounds of this invention are useful for the promotion of weight gain and food consumption in animals, e.g., poultry and swine. The addition of a low level of one or more of the herein described quinoxaline-di-N-oxides in feed or drinking solution at a level of from 0.1 mg/kg to 100 mg/kg of body weight per day over a major portion of the animal's active growth period results in an acceleration of the rate of growth and improves feed efficiency (the number of pounds of feed required to produce a pound of weight gain).
The following Examples illustrate the preparation of compounds of formula (IV) according to the invention.
f
EXAMPLE 1
4
Methyl 3-(5-hydroxymethyl-2-quinoxalinylmethylene)carbazate N ,N 20 dioxide (A)
4
A suspension of 2-bromomethyl-3-hydroxymethyl-quinoxaline,N ,N dioxide (6 mmoles) in acetonitrile (70 ml) was heated to reflux with stirring. Powdered anhydrous potassium carbonate (6.52 mmoles) and H-methoxycarbonyl-N'-trifylkydrazine (6.6 mmoles) were added to the suspension in one portion. A solid separated from the resulting ' incipient solution within a few minutes. The mixture was heated
440ββ
- 7 at reflux for a total of 1.5 hours. The solid was collected, washed successively with two 20 ml portions each of acetonitrile and ether, and dried to constant weight. The crude product was suspended in 5% sodium bicarbonate (50 ml) for 30 minutes, collected, washed with
. water, and then recrystallized from acetic acid (30 ml). The recrystallized product was washed with two 20 ml portions of acetic aeid/ether (1:1) and then with two 20 ml portions of ether to give the product (A) in 27% yield, m.p. 20S~210°C (dec.),
EXAMPLE 2
The method of Example 1 was repeated employing the appropriate
4
3-substituted~2~bromomethylguinoxaline, N ,N -dioxide to obtain the following compounds having the formula:
R4 M.P. , (°C.) % Yield (B) CH(OH)CH3 145 (dec.) 12 (C) c°c6h5 22C (dec.) 57 (E) COCH3 238 (dec.) 5
Table X illustrates the antibacterial spectra of the hitherto unreported compounds. These tests were conducted by preparing tubes of nutrient broth with gradually increasing concentrations of each compound and then seeding the broths with the particular organism specified. The minimal inhibitory concentration indicated in Table I is the minimal concentration of the compound (in micrograms/ml) at v/hioh the microorganism failed to grow. The tests were conducted under standardized conditions as described in Proc. Soc. Exp. Biol.
a Med., 122, 1107, (1966).
Table I
Minimum Inhibitory Concentration (Micrograms/ml) of Compound
Organism (A) (B) (C) (B) 5 Staphylococcus aureus 01A005 5.12 3.12 <0.39 0.7S 01A106 3.12 3.12 <0.39 0.78 Escherichia coli 51A203 3.12 6.25 6.25 1.56 51A26S 0.73 6.25 6.25 1.56 S1A218 3.12 6.25 6.25 6.25 10 Streptococcus pyogenes 020203 <0.39 0.78 <0.39 <0.32 Streptococcus equi C2I001 < 0.39 1.56 <0.39 <0.39 Salmonella typhimu- 58D001 3.12 12.5 25 3.12 riuxn S8D011 1.55 12.5 50 3.12 Salmonella dublin 58U001 3.12 6.25 12.5 3.12 IS Salmonella cholerae- 58B242 3.12 6.25 12.5 3.12 suls Pasteurella multocida 59A001 < 0.39 3.12 6.25 0.78 59A002 < 0.39 3.12 12.5 1.56 59A006 < 0.39 — — * —
EXAMPLE 3
The method of Example 1 may be repeated employing appropriate 1 4
3-substituted-2-chloromethylquinoxaline, N ,u -dioxides to obtain compounds with comparable antibacterial activities having the formula:
4468 S
- 10 ch2ch2oh chohch2ch3
COCH2CH3
COCH2CH2CH3
Claims (5)
1. A compound of the formula: C£t=N-NH-COOCEL ---(IV) wherein κ is hydroxyalkyl containing 1 to 6 carbon atoms, alkanoyl 5 containing 2 to 7 carbon atoms, or benzoyl. '4
2. A compound as claimed in claim 1 in which R is hydroxymethyl.
3. A compound as claimed in claim 1 in which R is 1-hydroxyethyl.
4. A compound as claimed in claim 1 in which R is acetyl.
5. A compound as claimed in claim 1 xn whxch R is benzoyl
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69626376A | 1976-06-15 | 1976-06-15 | |
IE1040/77A IE44684B1 (en) | 1976-06-15 | 1977-05-20 | Process for producing methyl 3-2(2-quinoxylinylmethylene) carbazate-n1,n4-dioxides |
Publications (2)
Publication Number | Publication Date |
---|---|
IE44685L IE44685L (en) | 1977-12-15 |
IE44685B1 true IE44685B1 (en) | 1982-02-24 |
Family
ID=26319034
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1629/81A IE44685B1 (en) | 1976-06-15 | 1977-05-20 | Methyl 3-(2-quinoxalinylmethylene)carbazate-n1,n4-dioxides |
IE1630/81A IE44686B1 (en) | 1976-06-15 | 1977-05-20 | N-methoxycarbonyl-n1-sulfonylhydrazines |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1630/81A IE44686B1 (en) | 1976-06-15 | 1977-05-20 | N-methoxycarbonyl-n1-sulfonylhydrazines |
Country Status (1)
Country | Link |
---|---|
IE (2) | IE44685B1 (en) |
-
1977
- 1977-05-20 IE IE1629/81A patent/IE44685B1/en not_active IP Right Cessation
- 1977-05-20 IE IE1630/81A patent/IE44686B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IE44685L (en) | 1977-12-15 |
IE44686L (en) | 1977-12-15 |
IE44686B1 (en) | 1982-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA10242A (en) | Crystalline Cephalic Acid Additive Salts with Acid Processes for Their Preparation Medicines Containing Them and Their Use | |
SU1050563A3 (en) | Process for preparing derivatives of 3,4,5-trihydroxypiperidine | |
JPH0631301B2 (en) | Antibacterial 9-deoxo-9a-allyl and propargyl-9a-aza-9a-homoerythromycin A derivatives | |
US4366311A (en) | Novel dianemycin derivative | |
US4100284A (en) | 1,4-Dioxo- and 4-oxoquinoxaline-2-carboxaldehyde sulfonylhydrazones and certain derivatives thereof | |
Jackson et al. | Crystalline β-Methyl-D-ribopyranoside1 | |
IE44685B1 (en) | Methyl 3-(2-quinoxalinylmethylene)carbazate-n1,n4-dioxides | |
GB1591873A (en) | Methyl 3-(2-quinoxalinylmethylene)carbazate-n1,n4-dioxides | |
US3759898A (en) | Synthesis of alpha-(carbo(5-indanyloxy)) benzylpenicillin | |
US3911011A (en) | 3,5-Dinitroaniline derivatives | |
US4174391A (en) | Spiramycin esters | |
US3767657A (en) | Process for the preparation of quinoxaline di n oxides | |
SU869560A3 (en) | Method of producing substituted 7-(5-oxo-4-phenylimidazolidin-1-yl)-3-chloro-3-cephem-4-carboxalic acids | |
IE43252B1 (en) | Quinoxaline-1,4-dioxides | |
KR900004418B1 (en) | Process for preparing penem esters | |
US3991053A (en) | Antibacterial 1,3-dihydrofuro[3,4-b]quinoxaline 4,9-dioxides | |
US3423457A (en) | Substitution products of 7-chloro-6-demethyltetracycline | |
US3954775A (en) | Thiazolo(5,4-f)quinoline-8-carboxylic acid derivatives | |
US3005024A (en) | 1:3:3-acetaldehyde-ammonia adducts of tetracycline and its analogs | |
US3859362A (en) | Alkyl-2,3,3-triiodoallyl ethers and process for their preparation and a composition containing the same | |
US4007184A (en) | Substituted alkyl esters of quinoxaline-di-N-oxide-2-carboxylic acid | |
CA1081703A (en) | Zearalin ethers | |
US4785078A (en) | Transformation product of thiosporamicin | |
US3915975A (en) | Substituted alkyl esters of quinoxaline-di-N-oxide-2-carboxylic acid | |
US3483257A (en) | Conjugated acetylenic ketones and method for preparation of same and use of same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |